Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mammon who wrote (12966)	6/18/2014 6:00:04 PM
From: Howard Williams	Read Replies (1) \| Respond to of 13111

DTIC and TMZ are the approved "Standard of Care" drugs for Stage 3 melanoma. Worldwide, there are about 25,000 new Stage 3 melanoma patients yearly and over 300,000 existing Stage 3 patients. The USA accounts for just under a half of those numbers. We've been told PVCT needs ~210 Stage 3 patients for the Phase 3 trial, or less than 1/10 of one percent of the worldwide pool. This suggests it should not be difficult to get adequate patients.